original ) (raw )Myocardial salvaging effects and mechanisms of dipeptidyl peptidase-IV inhibitor Vildagliptin in experimental diabetes
rajesh suman
2016
View PDFchevron_right
Effect of Hypoglycemic Agents on Ischemic Preconditioning in Patients With Type 2 Diabetes and Symptomatic Coronary Artery Disease
Priscyla Girardi , Desiderio Favarato , Cibele Garzillo
Diabetes Care, 2013
View PDFchevron_right
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure
Je Schneider
JACC. Heart failure, 2018
View PDFchevron_right
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
Shah Begum
Cardiovascular Diabetology, 2013
View PDFchevron_right
Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Matthew Silva
Journal of Clinical Pharmacy and Therapeutics, 2004
View PDFchevron_right
Does dipeptidyl peptidase IV inhibitor increase the risk of heart failure? A cardiologist’s paradox
tejas patel
Cardiovascular Endocrinology, 2014
View PDFchevron_right
Effect of Vildagliptin on Cardiac and Endothelial Function as Compared to Metformin in Type 2 Diabetes Mellitus Patients with Cardiomyopathy
International Journal of Research & Review (IJRR)
https://www.ijrrjournal.com/IJRR\_Vol.7\_Issue.12\_Dec2020/Abstract\_IJRR0033.html , 2020
View PDFchevron_right
The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury
David Aguilar
Basic Research in Cardiology, 2011
View PDFchevron_right
Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist
Wiek Van Gilst
International Journal of Cardiology, 2013
View PDFchevron_right
Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus
Carmen Serban
Diabetes therapy : research, treatment and education of diabetes and related disorders, 2017
View PDFchevron_right
Cardiovascular Effect of Dipeptidyl Peptidase-4 Inhibitor in Diabetic Patients: A Review
Sharvan Rampersad
2016
View PDFchevron_right
Anti-diabetic Agents and the Potentials for Reducing Cardiovascular Risks in Type-2 Diabetes Mellitus
Aihanuwa Eregie
Annals of Health Research
View PDFchevron_right
Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”
Antonis Manolis
Drugs, 2018
View PDFchevron_right
Antidiabetic Treatment In Diabetic Patients With Coronary Artery Disease
Mehmet sıddık Ulgen
Electronic Journal of General Medicine
View PDFchevron_right
THEEFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETES MELLITUS Original Article
International Journal of Pharmacy and Pharmaceutical Sciences (IJPPS)
International Journal of Pharmacy and Pharmaceutical Sciences, 2017
View PDFchevron_right
Sulfonylurea antidiabetics are associated with lower risk of out‐of‐hospital cardiac arrest: Real‐world data from a population‐based study
Talip Emre Eroglu
British Journal of Clinical Pharmacology, 2021
View PDFchevron_right
Current concepts of cardiovascular diseases in diabetes mellitus
Jaffar Raza
International Journal of Cardiology, 2003
View PDFchevron_right
Effects of Incretin Mimetic Drugs on Diabetic Cardiovascular Functions
ebru inan
2017
View PDFchevron_right
Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach
Federico Mercanti
Acta Diabetologica, 2013
View PDFchevron_right
Type 2 diabetes mellitus and myocardial ischemic preconditioning in symptomatic coronary artery disease patients
Priscyla Girardi , Cibele Garzillo
Cardiovascular Diabetology, 2015
View PDFchevron_right
Combination of Vildagliptin and Ischemic Postconditioning in Diabetic Hearts as a Working Strategy to Reduce Myocardial Reperfusion Injury by Restoring Mitochondrial Function and Autophagic Activity
Milad Zadi Heydarabad
Advanced Pharmaceutical Bulletin, 2018
View PDFchevron_right
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non–ST-elevation myocardial infarction: results from …
Joe Alexander
Circulation, 2000
View PDFchevron_right
Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence
Andres Suarez
World Journal of Diabetes, 2019
View PDFchevron_right
Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi-database, non-interventional post-authorization safety study
Carmen Serban
Diabetes, obesity & metabolism, 2017
View PDFchevron_right
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
Rohan Rajaratnam
Cardiovascular diabetology, 2017
View PDFchevron_right
[Diabetes mellitus and the heart]
Claudio Pinho
Arquivos Brasileiros de Cardiologia
View PDFchevron_right
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Stefan Agewall
European heart journal, 2017
View PDFchevron_right
Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment
Richard Parsons
Diabetes Care, 1998
View PDFchevron_right
Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study
Christian Torp-pedersen
Cardiovascular Diabetology, 2010
View PDFchevron_right
Effect of sulfonylureas on attenuation of electrocardiographic ST- segment elevation during an acute myocardial infarction in diabetics
Naser Tadvi
International Journal of Basic & Clinical Pharmacology, 2018
View PDFchevron_right
Comparison of two sulfonylureas with high and low myocardial KATP channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes
Hans Bøtker
Diabetologia, 2011
View PDFchevron_right